Literature DB >> 27316702

Fullerenes and their derivatives as inhibitors of tumor necrosis factor-α with highly promoted affinities.

Gaoyin Wu1, Xuejiao J Gao1,2, Joonkyung Jang3, Xingfa Gao4.   

Abstract

Tumor necrosis factor-α (TNF-α) is a cell signalling protein involved in systemic inflammation in infectious and other malignant diseases. Physiologically, it plays an important role in regulating host defence, but its overexpression can lead to serious illnesses including cancer, autoimmune disease and inflammatory disease. Gadolinium-based metallofullerenols, e.g., Gd@C82(OH) x (x ≈ 22), are well known for their abundant biological activities with low toxicity experimentally and theoretically; however, their activity in direct TNF-α inhibition has not been explored. In this work, we investigated the inhibiting effects of four types of fullerene-based ligands: fullerenes, fullerenols, metallofullerenes, and metallofullerenols. We reported previously that fullerenes, metallofullerenes and their hydroxylated derivatives (fullerenols) can reside in the same pocket of the TNF-α dimer as that of SPD304-a known inhibitor of TNF-α [He et al. (2005) Science 310:1022, 18]. Ligand docking and binding free energy calculations suggest that, with a similar nonpolar interaction dominated binding pattern, the fullerene-based ligands, C60, C60(OH)12, Gd@C60, C82, C82(OH)12, Gd@C82, Gd@C82(OH)13 and Gd@C82(OH)21, have larger affinity than currently known inhibitors, and could be used to design novel inhibitors of TNF-α in the future. Graphical Abstract Fullerene-material/TNF-α.

Entities:  

Keywords:  Binding free energy; Fullerene; Inhibitor; Molecular docking; TNF-α

Mesh:

Substances:

Year:  2016        PMID: 27316702     DOI: 10.1007/s00894-016-3019-8

Source DB:  PubMed          Journal:  J Mol Model        ISSN: 0948-5023            Impact factor:   1.810


  30 in total

1.  Eriocalyxin B inhibits nuclear factor-kappaB activation by interfering with the binding of both p65 and p50 to the response element in a noncompetitive manner.

Authors:  Chung-Hang Leung; Susan P Grill; Wing Lam; Wenli Gao; Han-Dong Sun; Yung-Chi Cheng
Journal:  Mol Pharmacol       Date:  2006-08-29       Impact factor: 4.436

Review 2.  MAP kinase p38 inhibitors: clinical results and an intimate look at their interactions with p38alpha protein.

Authors:  Matthew R Lee; Celia Dominguez
Journal:  Curr Med Chem       Date:  2005       Impact factor: 4.530

3.  BMS-345541 is a highly selective inhibitor of I kappa B kinase that binds at an allosteric site of the enzyme and blocks NF-kappa B-dependent transcription in mice.

Authors:  James R Burke; Mark A Pattoli; Kurt R Gregor; Patrick J Brassil; John F MacMaster; Kim W McIntyre; Xiaoxia Yang; Violetta S Iotzova; Wendy Clarke; Joann Strnad; Yuping Qiu; F Christopher Zusi
Journal:  J Biol Chem       Date:  2002-10-25       Impact factor: 5.157

4.  Multihydroxylated [Gd@C82(OH)22]n nanoparticles: antineoplastic activity of high efficiency and low toxicity.

Authors:  Chunying Chen; Gengmei Xing; Jiangxue Wang; Yuliang Zhao; Bai Li; Jun Tang; Guang Jia; Tiancheng Wang; Jin Sun; Li Xing; Hui Yuan; Yuxi Gao; Huan Meng; Zhen Chen; Feng Zhao; Zhifang Chai; Xiaohong Fang
Journal:  Nano Lett       Date:  2005-10       Impact factor: 11.189

Review 5.  Biological characterizations of [Gd@C82(OH)22]n nanoparticles as fullerene derivatives for cancer therapy.

Authors:  Jie Meng; Xingjie Liang; Xiaoyuan Chen; Yuliang Zhao
Journal:  Integr Biol (Camb)       Date:  2013-01       Impact factor: 2.192

Review 6.  Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat.

Authors:  H S Rasmussen; P P McCann
Journal:  Pharmacol Ther       Date:  1997       Impact factor: 12.310

7.  AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility.

Authors:  Garrett M Morris; Ruth Huey; William Lindstrom; Michel F Sanner; Richard K Belew; David S Goodsell; Arthur J Olson
Journal:  J Comput Chem       Date:  2009-12       Impact factor: 3.376

Review 8.  Safety of tumour necrosis factor-alpha antagonists.

Authors:  Dinesh Khanna; Maureen McMahon; Daniel E Furst
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

9.  Non-destructive inhibition of metallofullerenol Gd@C(82)(OH)(22) on WW domain: implication on signal transduction pathway.

Authors:  Seung-gu Kang; Tien Huynh; Ruhong Zhou
Journal:  Sci Rep       Date:  2012-12-11       Impact factor: 4.379

10.  LMP-420, a small-molecule inhibitor of TNF-alpha, reduces replication of HIV-1 and Mycobacterium tuberculosis in human cells.

Authors:  Soichi Haraguchi; Noorbibi K Day; Wasu Kamchaisatian; Macarena Beigier-Pompadre; Steffen Stenger; Nutthapong Tangsinmankong; John W Sleasman; Salvatore V Pizzo; George J Cianciolo
Journal:  AIDS Res Ther       Date:  2006-03-31       Impact factor: 2.250

View more
  4 in total

1.  Nanoparticle fullerol alleviates radiculopathy via NLRP3 inflammasome and neuropeptides.

Authors:  Li Jin; Mengmeng Ding; Azra Oklopcic; Bayan Aghdasi; Li Xiao; Ziyi Li; Vesna Jevtovic-Todorovic; Xudong Li
Journal:  Nanomedicine       Date:  2017-04-09       Impact factor: 5.307

2.  Fullerenes in Biology and Medicine.

Authors:  Edison Castro; Andrea Hernandez Garcia; Gerardo Zavala; Luis Echegoyen
Journal:  J Mater Chem B       Date:  2017-07-08       Impact factor: 6.331

3.  Water-Soluble, Alanine-Modified Fullerene C60 Promotes the Proliferation and Neuronal Differentiation of Neural Stem Cells.

Authors:  Haiyuan Ren; Jinrui Li; Ai Peng; Ting Liu; Mengjun Chen; Hongguang Li; Xiaojing Wang
Journal:  Int J Mol Sci       Date:  2022-05-20       Impact factor: 6.208

4.  Fullerene Derivatives as Lung Cancer Cell Inhibitors: Investigation of Potential Descriptors Using QSAR Approaches.

Authors:  Hung-Jin Huang; Olga A Kraevaya; Ilya I Voronov; Pavel A Troshin; Shan-Hui Hsu
Journal:  Int J Nanomedicine       Date:  2020-04-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.